Table 6.

Spearman’s correlation coefficient (r) among the investigated hsa-miRs’ expression levels’ fold changes in all CHCV-G4 patients (liver cirrhosis patients post-HCV) (n = 79).

	CHCV-G4 Patients (n = 79) miRs-Fold Change
	hsa-miR-21-5p		hsa-miR-155-5p		hsa-miR-192-5p		hsa-miR-199a-5p
Data/Characteristics (Unit)	r	p-Value	r	p-Value	r	p-Value	r	p-Value
Age (Years)	0.004	NS	−0.004	NS	−0.060	NS	−0.054	NS
BMI (kg/m2)	0.103	NS	0.059	NS	−0.124	NS	−0.222	0.050 *
s. Insulin (mIU/L)	0.334	0.01 *	0.203	NS	−0.001	NS	−0.125	NS
AFP (ng/mL)	0.534	<0.001 *	0.371	0.001 *	−0.092	NS	−0.023	NS
AST (U/L)	0.104	NS	−0.001	NS	0.070	NS	0.03	NS
ALT (U/L)	−0.172	NS	−0.138	NS	0.114	NS	−0.068	NS
ALP (U/L)	−0.263	0.019 *	−0.163	NS	−0.043	NS	0.069	NS
GGT (U/L)	−0.144	NS	−0.120	NS	0.106	NS	0.145	NS
TAG (mg/dL)	0.241	0.033 *	0.180	NS	−0.144	NS	0.133	NS
TC (mg/dL)	0.235	0.037 *	0.120	NS	−0.230	0.042 *	0.075	NS
HDL-C (mg/dL)	−0.110	NS	−0.064	NS	−0.062	NS	−0.064	NS
TAG/HDL-C	0.195	NS	0.115	NS	−0.085	NS	0.111	NS
PLR	−0.045	NS	0.137	NS	−0.119	NS	0.298	0.008 *
Number of liver masses	−0.027	NS	−0.038	NS	0.010	NS	−0.018	NS
Insulin resistance	0.303	0.02 *	0.103	NS	0.140	NS	−0.090	NS

Spearman correlation coefficient (r) was calculated using SPSS software. * Significant correlation at p < 0.05 level (2-tailed); NS, non-significant; LC, liver cirrhosis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; BMI, body mass index; DM, diabetes mellitus; HCC, hepatocellular carcinoma; HDL, high-density lipoprotein; GGT, gamma-glutamyl transferase; LC, liver cirrhosis; PLR, platelet lymphocyte ratio; NLR, neutrophil–lymphocyte ratio; s. insulin, serum insulin; TC, total cholesterol; TAG, triacylglycerol.